Shattuck Labs, Inc.
FLT3L-BASED CHIMERIC PROTEINS
Last updated:
Abstract:
The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
Status:
Application
Type:
Utility
Filling date:
13 Aug 2020
Issue date:
18 Feb 2021